For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Atai Therapeutics Inc.

USPTO Granted Patents = 17

EPO Patents = 2

Forward Citations = 36

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Glenn Short (7 out of 13 patents)

Robert B Perni (6 out of 57 patents)

Jacqueline L Salm (5 out of 11 patents)

4. Christopher G Witowski (5 out of 11 patents)

5. Tanweer A Khan (5 out of 17 patents)

6. Majed Fawaz (3 out of 12 patents)

7. Srinivas G Rao (2 out of 20 patents)

8. Holger Weis (1 out of 5 patents)

9. Emeline Maillet (1 out of 7 patents)

10. Prahlad Krishnan (1 out of 2 patents)

11. Glen Short (1 out of 1 patent)

12. Santnu Patel (1 out of 1 patent)

13. Prerak Patel (1 out of 1 patent)

14. Nicholas Morra (1 out of 4 patents)

15. Benjamin Robert Difrancesco (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 12729182 - Crystalline forms of N,N-dimethyltryptamine and methods of using the same (2026-09-08),

2. 12691098 - Compositions of matter and pharmaceutical compositions (2026-07-28),

3. 12685722 - Compositions of matter and pharmaceutical compositions (2026-07-21),

4. 12642787 - Compositions of matter and pharmaceutical compositions (2026-06-02),

5. 12606525 - Dimethyltryptamine analogues as nitric oxide delivery drugs (2026-04-21),

6. 12472163 - Compositions of matter and pharmaceutical compositions (2025-11-18),

7. 12396982 - Compositions of matter and pharmaceutical compositions (2025-08-26),

8. 12378194 - N, n-dimethyltryptamine salts and crystalline salt forms (2025-08-05),

9. 12351537 - Dimethoxyphenylalkylamine activators of serotonin receptors (2025-07-08),

10. 12344570 - Aminotetraline activators of serotonin receptors (2025-07-01),

11. 12343319 - Compositions and methods for treatment of diseases and disorders (2025-07-01),

12. 12128027 - N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof (2024-10-29),

13. 12097332 - Systems, devices, and methods for generating and manipulating objects in a virtual reality or multi-sensory environment to maintain a positive state of a user (2024-09-24),

14. 12065405 - Prodrugs and conjugates of dimethyltryptamine (2024-08-20),

15. 12016866 - Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids (2024-06-25),

Company Overview

Atai Therapeutics Inc. is a biopharmaceutical company based in New York, specializing in the development of innovative therapies for mental health disorders. The organization focuses on advancing a diverse portfolio of compounds, including psychedelic and non-psychedelic treatments, aimed at addressing unmet medical needs in psychiatry. Atai leverages cutting-edge research and technology to explore novel approaches to mental health, fostering collaborations to enhance its therapeutic offerings and drive scientific advancements in the field.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

17 Patents

#455 in New York, NY

#1,100 in New York

#18,881 in US

#35,887 in the World

New York, NY, United States of America

Atai Therapeutics Inc.

Forward Citations = 36

24 inventors:

Glenn Short (7 out of 13 patents)

Robert B Perni (6 out of 57 patents)

Jacqueline L Salm (5 out of 11 patents)

4. Christopher G Witowski (5 out of 11 patents)

5. Tanweer A Khan (5 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Atai Therapeutics Inc.. Retrieved from https://idiyas.com/company/atai-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…